Drug in clinical trials for breast cancer could also treat some blood cancers
Two new studies led by researchers at Washington University School of Medicine in St. Louis have identified a possible way to block the progression of several forms of blood cancer using a drug already in clinical trials against breast cancer.
Iron accelerates MDS progression
In this issue of Blood, Antypiuk et al, utilizing a murine model, demonstrate that iron overload (IOL), accumulated via a
How I Treat Higher-Risk MDS with Alain Mina, Rami S. Komrokji
FDA Approves Axatilimab in 9 Mg and 22 Mg Vial Sizes for GVHD
Axatilimab-csfr (Niktimvo), a CSF-1R–targeting agent that reduces the drivers of inflammation and fibrosis, has been approved by the FDA in 9 mg and 22 mg vial sizes to treat adult and pediatric patients with
COMMANDS: Long-Term Analysis, Changes in RBC Transfusion Burden, Hemoglobin Levels and ELEMENTS Trial
Panelists discuss how long-term analysis of the ELEMENTS trial reveals significant improvements in red blood cell (RBC) transfusion burden and
2025 Kansas City Patient and Family Conference
Here are links to the conference sessions from the 2025 Kansas City Patient and Family Conference:
Event Date:
Fri, 04/25/2025 - 5:30pm (EDT) to Sat, 04/26/2025 - 3:30pm (EDT)
Bone Marrow Disease(s):
Conference Event Type:
MDS and Keeping Hope - Donna's Story
Donna Gilbride explains her journey through diagnosis and treatment with MDS, or Myelodysplastic Syndromes.
Listen or read the transcript below.
Long, Hard, Road to Diagnosis - Shaquilla's Story
Shaquilla Gordon explains her journey with the bone marrow failure condition called PNH, or Paroxysmal Nocturnal Hemoglobinuria. Listen or read the transcript below.
Health-related quality of life and symptom-specific functional impairment among patients treated with parenterally administered complement inhibitors for paroxysmal nocturnal hemoglobinuria
Journal Title:
Annals of Hematology
Original Publication Date:
Nov 2024
Bone Marrow Disease(s):